评估单药纳武利尤单抗维持急性髓系白血病缓解的随机2期研究
这项多中心、开放标签、随机2期研究评估纳武利尤单抗作为不适合移植的急性髓系白血病首次完全缓解或伴血液学恢复不完全的完全缓解患者维持治疗的疗效。患者随机分配至观察组或纳武利尤单抗组(3 mg/kg 静脉注射,每2周一次,共46次)。纳武利尤单抗组无进展生存期13.2个月 vs 观察组10.9个月,总生存期53.9个月 vs 30.9个月,无进展生存期曲线无统计学显著差异;纳武利尤单抗组3级及以上不良事件27例(71%)vs 观察组5例(12%)(P < .001)。
要点
- 纳武利尤单抗维持治疗未能改善无进展生存期和总生存期。
- 纳武利尤单抗组3级及以上不良事件27例(71%)vs 观察组5例(12%)(P < .001)。
- 不良事件和严重不良事件增加但可预期且可控。
核心结论
- 急性髓系白血病化疗后纳武利尤单抗维持治疗未能改善无进展生存期和总生存期。
- 纳武利尤单抗组不良事件和严重不良事件增加,但可预期且可控。
研究设计与样本
- 多中心、开放标签、随机2期研究,纳入80例不适合干细胞移植的急性髓系白血病首次完全缓解或伴血液学恢复不完全的完全缓解患者。
- 患者分层后随机分配至观察组或纳武利尤单抗组(3 mg/kg 静脉注射,每2周一次,共46次)。
- 主要终点为无进展生存期,定义为至疾病复发或任何原因死亡的时间;次要终点包括总生存期和纳武利尤单抗给药后不良事件评估。
- 中位随访时间24个月(生存者中33个月)。
- 试验注册号NCT02275533。
主要发现
- 纳武利尤单抗组无进展生存期13.2个月 vs 观察组10.9个月;总体无进展生存期曲线无统计学显著差异。
- 纳武利尤单抗组中位总生存期53.9个月 vs 观察组30.9个月。
- 纳武利尤单抗组任何类型不良事件(无论归因)更多;纳武利尤单抗组3级及以上不良事件27例(71%)vs 观察组5例(12%)(P < .001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We conducted a multicenter, open-label, randomized phase 2 study to assess the efficacy of nivolumab (Nivo) as maintenance therapy for patients with acute myeloid leukemia (AML) in first complete remission (CR) or CR with incomplete hematologic recovery who were not candidates for stem cell transplant. Patients were stratified and randomized to observation (Obs) or Nivo (3 mg/kg IV every 2 weeks for 46 doses). The primary end point was progression-free survival (PFS) defined as time to disease relapse or death due to any reason. Secondary end points included overall survival (OS), and evaluation of adverse events (AEs) after Nivo administration. Eighty patients were enrolled with median duration of follow-up of 24 months (33 months among survivors). PFS was 13.2 months in the Nivo arm and 10.9 months in the Obs arm. Overall PFS curves were not statistically significantly different. The median OS was 53.9 months in the Nivo arm and 30.9 months in the Obs arm. There were more AEs of any type (regardless of attribution) on the Nivo arm; 27 patients (71%) on the Nivo arm had a grade ≥3 AE compared with 5 patients (12%) on the Obs arm (P < .001). Nivo maintenance after AML chemotherapy failed to improve the PFS and OS in this randomized phase 2 study. There were increased AEs and serious AEs (SAEs) with Nivo, but these AEs and SAEs were expected and manageable. This trial was registered at www.ClinicalTrials.gov as #NCT02275533.
引用
- Pyzer AR, Dillon LW, Sharon E, et al. Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia. Blood Adv. 2025. PMID: 39928953. doi:10.1182/bloodadvances.2024015176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。